Neurocrine Biosciences retained earnings (accumulated deficit) for the quarter ending December 31, 2024 were $0.029B, a 118.59% decline year-over-year.
Neurocrine Biosciences retained earnings (accumulated deficit) for 2024 were $0.029B, a 118.59% decline from 2023.
Neurocrine Biosciences retained earnings (accumulated deficit) for 2023 were $-0.157B, a 61.38% decline from 2022.
Neurocrine Biosciences retained earnings (accumulated deficit) for 2022 were $-0.407B, a 36.02% decline from 2021.